LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

Bristol-Myers Squibb Co.

Closed

Sector Healthcare

41.85 1.87

Overview

Share price change

24h

Current

Min

41.68

Max

41.86

Key metrics

By Trading Economics

Income

-14B

-12B

Sales

423M

12B

P/E

Sector Avg

13.011

23.904

EPS

-4.4

Dividend yield

3.565

Profit margin

-100.092

Employees

34,100

EBITDA

-13B

-8.6B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+25.11 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.56%

7.76%

Next Earnings

26 lip 2024

Next Dividend date

1 sie 2024

Next Ex Dividend date

5 lip 2024

Market Stats

By TradingEconomics

Market Cap

-1.8B

84B

Previous open

39.98

Previous close

41.85

News Sentiment

By Acuity

68%

32%

311 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Bristol-Myers Squibb Co. Chart

Related News

25 kwi 2024, 14:38 UTC

Earnings

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

25 kwi 2024, 11:52 UTC

Earnings

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

18 mar 2024, 10:14 UTC

Major Market Movers

2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma

13 mar 2024, 18:16 UTC

Major Market Movers

2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy

11 mar 2024, 22:07 UTC

Earnings
Major Market Movers

CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate

19 cze 2024, 05:30 UTC

Top News
Acquisitions, Mergers, Takeovers

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 maj 2024, 22:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 kwi 2024, 12:36 UTC

Earnings

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

25 kwi 2024, 12:31 UTC

Acquisitions, Mergers, Takeovers

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

25 kwi 2024, 11:31 UTC

Earnings

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

25 kwi 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

25 kwi 2024, 11:05 UTC

Earnings

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

25 kwi 2024, 11:05 UTC

Earnings

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

25 kwi 2024, 11:04 UTC

Earnings

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

25 kwi 2024, 11:04 UTC

Earnings

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

25 kwi 2024, 11:03 UTC

Earnings

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

25 kwi 2024, 11:03 UTC

Earnings

Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch

25 kwi 2024, 11:03 UTC

Earnings

Bristol-Myers Squibb 1Q International Revenue Relatively Flat at $3.4B >BMY

25 kwi 2024, 11:02 UTC

Earnings

Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B >BMY

25 kwi 2024, 11:02 UTC

Earnings

Bristol-Myers Squibb: $6.30/Share 1Q Impact From Acquired IPRD Charge, Licensing Income >BMY

25 kwi 2024, 11:00 UTC

Earnings

Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8% >BMY

25 kwi 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Loss/Shr $5.89 >BMY

25 kwi 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Rev $11.9B >BMY

25 kwi 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40 >BMY

25 kwi 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Loss $11.91B >BMY

4 kwi 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4 kwi 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

19 mar 2024, 15:00 UTC

Acquisitions, Mergers, Takeovers

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover -- IBD

18 mar 2024, 12:44 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics

26 lut 2024, 13:35 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Completes Acquisition Of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform >BMY

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

25.11% upside

12 Months Forecast

Average 52.46 USD  25.11%

High 75 USD

Low 37 USD

Based on 17 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

17 ratings

5

Buy

11

Hold

1

Sell

Technical Score

By Trading Central

41.2 / 42.57Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

311 / 369 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.